Imunotick Overview

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

  • Financing Rounds
  • 2

Imunotick General Information

Description

Developer of livestock vaccines designed to combat diseases and damage caused by ticks. The company utilizes a platform for developing recombinant multiantigen vaccines and maintains scientific cooperation agreements with research institutions to address tick-related diseases in cattle, providing the livestock industry with recombinant vaccines, multiantigen vaccines, hybrid peptides, vaccine kits, and biotechnological services.

Contact Information

Website
www.imunotick.com
Ownership Status
Out of Business
Financing Status
Formerly PE-Backed
Corporate Office
  • Sao Paulo
  • Brazil
Primary Industry
Other Commercial Products
Vertical(s)
Life Sciences
Corporate Office
  • Sao Paulo
  • Brazil

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imunotick Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Imunotick‘s full profile, request access.

Request a free trial

Imunotick Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Imunotick Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026044376-A1 Platform for developing recombinant multiantigen vaccines Pending 30-Aug-2024
EP-3581589-A1 Hybrid peptide, set of hybrid peptides, composition, uses of the hybrid peptide, method for inducing an immune response and kits Pending 09-Feb-2017
EP-3581589-A4 Hybrid peptide, set of hybrid peptides, composition, uses of the hybrid peptide, method for inducing an immune response and kits Pending 09-Feb-2017
US-11034735-B2 Hybrid peptide, set of hybrid peptides, composition, uses of the hybrid peptide, method for inducing an immune response and kits Active 09-Feb-2017
US-20200095289-A1 Hybrid peptide, set of hybrid peptides, composition, uses of the hybrid peptide, method for inducing an immune response and kits Active 09-Feb-2017 C07K14/29
To view Imunotick’s complete patent history, request access »

Imunotick FAQs

  • Where is Imunotick headquartered?

    Imunotick is headquartered in Sao Paulo, Brazil.

  • What industry is Imunotick in?

    Imunotick’s primary industry is Other Commercial Products.

  • Is Imunotick a private or public company?

    Imunotick is a Private company.

  • What is Imunotick’s current revenue?

    The current revenue for Imunotick is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process